BioCentury
ARTICLE | Emerging Company Profile

TenSixteen: Targeting dynamic genome to find driver mutations, catch cancer earlier 

Foresite, GV lead $40M A round to build data platform, Dx assay

January 28, 2022 6:48 PM UTC

TenSixteen Bio is launching with a $40 million series A round to interrogate a new source of disease-causing mutations in hematopoietic stem cells that could help stop the progression of cancer and cardiovascular disease.

TenSixteen Bio Inc. was co-founded by Foresite Labs, the accelerator of Foresite Capital, and CEO Mark Chao, who co-founded anti-CD47 pioneer Forty Seven Inc. and became VP of oncology at Gilead Sciences Inc. (NASDAQ:GILD) after the large-cap biopharma acquired the biotech for $4.9 billion in 2020...



Access The Full Article